Yael P Mosse MD

Clinical Trials

• N99-02: Melphalan and Buthionine Sulfoximine Start of enrollment: 2001 Aug 01

  Completed

  Phase 1

• ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment Start of enrollment: 2007 Jan 01

  Completed

  Phase 2

• A Phase I/II Study of MLN8237, an Oral Selective Small Molecule Inhibitor of Aurora A Kinase, in Children With Relapsed/Refractory Solid Tumors Start of enrollment: 2008 Sep 01
• N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma Start of enrollment: 2009 Dec 01

  Completed

  Phase 1

• Studying Tumor Samples From Young Patients With Neuroblastoma Start of enrollment: 2008 Dec 01

  Completed

• Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Start of enrollment: 2009 Sep 21

  Completed

  Phase 1, Phase 2

• N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma Start of enrollment: 2010 Mar 01

  Completed

  Phase 1

• Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia Start of enrollment: 2011 Feb 01

  Completed

  Phase 2

• 131-I-MIBG Therapy for Refractory Neuroblastoma, Expanded Access Protocol

  AVAILABLE

• Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin Start of enrollment: 2010 Oct 04

  ACTIVE_NOT_RECRUITING

  PHASE1

• Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma Start of enrollment: 2010 Dec 01

  Completed

  Phase 1

• Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma Start of enrollment: 2013 Feb 04

  ACTIVE_NOT_RECRUITING

  PHASE1

• N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan Start of enrollment: 2014 Jan 16

  COMPLETED

  PHASE1

• 131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat Start of enrollment: 2014 Jul 01

  Completed

  Phase 2

• NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922) Start of enrollment: 2017 Sep 05

  ACTIVE_NOT_RECRUITING

  PHASE1

• A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma Start of enrollment: 2020 Jun 11

  ACTIVE_NOT_RECRUITING

  PHASE1

• MIBG With Dinutuximab +/- Vorinostat Start of enrollment: 2018 Sep 12

  ACTIVE_NOT_RECRUITING

  PHASE1

  Roles: Contact

• Neuroblastoma Biology Study

  RECRUITING

  Roles: Contact

• GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma Start of enrollment: 2023 May 23

  RECRUITING

  PHASE1

  Roles: Contact

• NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial Start of enrollment: 2024 Dec 16

  RECRUITING

  PHASE2

  Roles: Contact

• Join now to see all